CC-223: Clinical Trials

1 trial of CC-223, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed. 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11Completed 1
Phase 21Completed 1

Follow CC-223: new trials by email Literature Review of CC-223 trials Research Report on CC-223

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
CC-223 - Multiple Myeloma, Diffuse Large B-Cell Lymphoma
Phase 1 / Phase 2CompletedCelgene2262010-07-202022-12-13

Conditions studied

Carcinoma, Hepatocellular (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Glioblastoma (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Multiple Myeloma (1)

Sponsors

Celgene (1)

Countries

France (1)  ·  Spain (1)  ·  United Kingdom (1)  ·  United States (1)